Aurobindo Pharma Limited

BSE
AUROPHARMA
paper.types.company
Rentabilité sur six mois: -3.46%
Rendement en dividendes: 0%

Calendrier des promotions Aurobindo Pharma Limited

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Aurobindo Pharma Limited

Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally.

plus de détails
The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

ISIN
INE406A01037
Industry
Pharmaceuticals
Sector
Health Care
Валюта
inr
Валюта отчета
inr
Див.доход ао
0.7306
Дивиденд ао
4.5
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 2.08 7
P/BV 2 7
P/E 18.84 7
Efficacité
Nom Signification Grade
ROA 7.47 2
ROE 11.2 4
ROIC 6.91 2
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0.7143 7.14
Croissance moyenne du dividende -6.1 0
Devoir
Nom Signification Grade
Debt/EBITDA 1.58 7
Debt/Ratio 0.1401 10
Debt/Equity 0.2116 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 26.24 4
Rentabilité Ebitda, % 2.24 1
Rentabilité EPS, % 12.08 2
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1 150.65 ₹ 0 ₹ 0 ₹ 0 % 0 % 0 %
common.calendar.number_days.7d 1 161.45 ₹ 1 150.65 ₹ 1 170.6 ₹ -0.93 % 0 % 0 %
common.calendar.number_days.30d 1 196.45 ₹ 1 136.25 ₹ 1 206.1 ₹ -3.83 % 0 % 0 %
common.calendar.number_days.90d 1 056.5 ₹ 1 056.5 ₹ 1 257.6 ₹ 8.91 % 0 % 0 %
common.calendar.number_days.180d 1 191.85 ₹ 1 051.75 ₹ 1 351.4 ₹ -3.46 % 0 % 0 %
common.calendar.number_days.1y 1 551.25 ₹ 1 051.75 ₹ 1 574.95 ₹ -25.82 % 0 % 0 %
common.calendar.number_days.3y 539.85 ₹ 403.9 ₹ 1 574.95 ₹ 113.14 % 0 % 0 %
common.calendar.number_days.5y 779.05 ₹ 403.9 ₹ 1 574.95 ₹ 47.7 % 0 % 0 %
common.calendar.number_days.10y 0 ₹ 294.35 ₹ 1 574.95 ₹ 0 % 0 % 0 %
common.calendar.number_days.ytd 1 129.8 ₹ 1 051.75 ₹ 1 348.65 ₹ 1.85 % 0 % 0 %

Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Mettu Madan Mohan Reddy Whole-Time Director 52.35M 1960 (65 années)
Mr. Santhanam Subramanian Chief Financial Officer 21.06M 1961 (64 année)
Mr. Sanjeev Indravadan Dani COO & Head of Formulations N/A 1960 (65 années)
Dr. S. Vijaya Kumar President of Technical N/A 1966 (59 années)
Mr. Arvind Bothra Head of Investor Relations & Corporate Communications N/A
Mr. B. Adi Reddy Compliance Officer & Company Secretary 4.76M
Mr. G. P. Prasad Senior Vice President of Global Finance & Operations N/A
Dr. Sudhir Bimal Singhi Head of Global Finance Operations N/A 1969 (56 années)
Mr. Kambam Nithyananda Reddy Vice Chairman & MD 1958 (67 années)
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D. President of Biologics, CEO of Biologics, Vaccines and Peptid & Director 1981 (44 année)

Informations sur l'entreprise

Adresse: India, Hyderabad, Galaxy Plot No. 1 - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.aurobindo.com